



**Minutes of Annual General Meeting 2026 (No. 48)**  
**Aikchol Hospital Public Company Limited**

**Date and Venue**

The meeting was held on Thursday 23<sup>rd</sup> April 2026 at 10:00 a.m. at the Conference Room 1 on 3<sup>rd</sup> Floor of Aikchol Hospital Angsila, No.31/2 Moo 2, Angsila Road, Samed Sub-district, Muang Chonburi province.

**Directors in attendance At meeting room 1, 3<sup>rd</sup> floor, Aikchol Hospital Angsila**

- |    |                       |                    |   |
|----|-----------------------|--------------------|---|
| 1) | Mr. Apirag            | Vanich             | Chairman  |
| 2) | Ms. Kanchana          | Vanich             | Director  |
| 3) | Ms. Oranuj            | Vanich             | Director  |
| 4) | Mrs. Thitawat         | Pothanant          | Independent Director /<br>Member of Audit Committee /<br>Member of the Nomination and Remuneration<br>Committee |
| 5) | Assoc.Prof.Dr.Sarayut | Rueangsuwan, Ph.D. | Director / Member of the Nomination and<br>Remuneration Committee   |
| 6) | Assoc.Prof.Pongsak    | Yuktanandana, M.D. | Independent / Member of Audit Committee   |
| 7) | Mr. Kiattiporn        | Sirichaisakul      | Independent / Member of Audit Committee   |

**The proportion of directors attending the meeting was 100% of all directors.**

**Executives in attendance At meeting room 1, 3<sup>rd</sup> floor, Aikchol Hospital Angsila**

- |     |                   |                         |   |
|-----|-------------------|-------------------------|---|
| 1)  | Mr. Bordin        | Sabsomboon              | The Person Nominated for Election as<br>Director                            |
| 2)  | Mr. Siriphot      | Manoch                  | Assistant Chairman of the Executive Officer,<br>Corporate Strategy Division |
| 3)  | Mr. Nopparuj      | Potcharakotchanun, M.D. | Hospital Director (Aikchol Hospital)  |
| 4)  | Mr. Kesada        | Chandsawang, M.D.       | Hospital Director (Aikchol Hospital Angsila)                                |
| 5)  | Mrs. Pariyanath   | Chalermchuang           | Chief Accounting and Finance Officer  |
| 6)  | Ms. Daraphan      | Sakornsathien           | Chief Marketing Officer   |
| 7)  | Ms. Chalapim      | Chaisuttinan            | Director of Nursing Department  |
| 8)  | Mr. Sidthiphot    | Manoch                  | Deputy Director of Accounting and Finance                                   |
| 9)  | Ms. Thanatchaporn | Sukha                   | Financial & Accounting Manager  |
| 10) | Mrs. Wilailux     | Srisuwan                | Company Secretary   |



### **Attendee**

- 1) Mr. Pipat Pipatphajong Legal Advisor from ILCT Co.,Ltd.
- 2) Ms. Praneetsin Foythong Representative of Auditor from Dharmniti Auditing Co.,Ltd.
- 3) Ms. Dalalda Chitrengam Representative of Auditor from Dharmniti Auditing Co.,Ltd.

### **Preliminary Proceedings**

Mrs. Wilailux Srisuwan, the Company Secretary, informed the meeting that the Company has a total of 149,909,264 paid-up ordinary shares. In this meeting, there were 6 shareholders attending in person, representing 27,141,988 shares, and 28 shareholders attending by proxy, representing 59,260,377 shares. In total, 34 shareholders and proxies attended the meeting, representing 86,402,365 shares or 57.6364% of the total issued shares. This constitutes a quorum in accordance with the law and Article 36 of the Company's Articles of Association, which stipulates that at a shareholders' meeting, there must be at least 25 shareholders and proxies (if any) or not less than half of the total number of shareholders, and they must hold no less than one-third of the total issued shares to form a quorum.

Mr. Apirag Vanich, Chairman of the Board of Directors, presided over the meeting (the "Chairman") and declared the 2026 Annual General Meeting open. The Chairman introduced the directors, company executives, and external attendees, including representatives from the legal advisors, the external auditor, and the company's legal counsel. The Chairman then assigned Ms. Wilailuck Srisuwan, the Company Secretary, to explain the voting procedures. The Company Secretary informed the meeting that the Company would like to clarify the procedures for inquiries, voting, and vote counting as follows:

1. The voting method in the Company's shareholders' meeting, each agenda was as follows;

- (1) Shareholders or proxies have votes equal to the number of shares held. By using voting, disapproving shareholders or abstain from voting, raise your hand for the staff to collect the ballot.

- (2) Shareholder who submits a proxy form B to allow others to attend the meeting or assign it to directors or independent directors to vote. Also requiring proxies to vote according to the wishes of the shareholders or proxies. The company will vote according to the wishes of the shareholders or proxies.

Custodians appointed by foreign investors to hold and safeguard their shares may vote with all their voting rights or divide them up into votes of approval, disapproval, or abstention for each agenda item, but the total votes cast on each item may not exceed their voting rights.

2. The minutes of the 47th Annual General Meeting of Shareholders, held on April 18, 2025, were disclosed by the Company via the corporate website and the Stock Exchange of Thailand's channels within the required timeframe. Shareholders were given the opportunity to review and



propose amendments to the minutes; however, no amendments were requested. Nevertheless, a copy of the minutes of the 47th meeting has been attached as Enclosure 1 to the invitation notice for this 48th Annual General Meeting of Shareholders.

3. The Company allows shareholders or proxies to raise questions after the presentation of each agenda item. Those who wish to ask questions are requested to raise their hands, state their full name and surname, and specify whether they are attending as a shareholder or as a proxy. Once all questions from shareholders have been addressed, the Company Secretary will announce the commencement of the voting process for each agenda item, allowing 30 seconds per agenda.

**Agenda 1 To acknowledge the report of the Board of Directors regarding business operations and the report 56-1 One Report for the year 2026**

The Chairman informed the meeting that this agenda item is to acknowledge the Company's operating results and the Board of Directors' 2025 Annual Report (Form 56-1 One Report). The details are provided in Enclosure 2 (the 2025 Form 56-1 One Report), which has been delivered to all shareholders along with the invitation notice for this Annual General Meeting.

The Chairman assigned the executive team to present the reports: Mr.Nopparuj Potcharakotchanun, M.D. reported on the operating results of Aikchol Hospital; Mr.Kesada Chandsawang, M.D. reported on Aikchol Angsila Hospital. Ms.Daraphan Sakornsatian reported on marketing and sales promotion activities; and Mr. Sittipot Manoch reported on the overall accounting and financial performance of the Company, as follows:

**Mr. Nopparuj Potcharakotchanun, M.D.** Presenting the performance of Aikchol Hospital

In 2025, the operating results of Aikchol Hospital included the following: (1) Heart Center, (2) Spine and Orthopedic Center, (3) Diabetes Center, and (4) Emergency Department. These centers have been developed to meet the needs of patients of all genders and ages.

**Heart Center** The Heart Center provides comprehensive cardiac care, covering medical treatment, in-depth diagnosis, and specialized procedures. Over the past year, the center organized activities to promote access to heart screenings through marketing campaigns and promotions for Echocardiograms and Exercise Stress Tests (EST). These screenings enable early detection of coronary artery abnormalities, allowing patients to receive timely diagnosis and treatment, such as Percutaneous Coronary Intervention (PCI) using balloons and stents. Additionally, the center provides treatment for tachycardia and cardiac arrhythmia through Cardiac Ablation, as well as surgical implantation of Automated Implantable Cardioverter Defibrillators (AICD) and Pacemakers.

**Spine Center** The Spine and Orthopedic Center provides comprehensive care for patients with bone, joint, and spinal conditions, ranging from diagnosis and medical treatment to physical therapy and surgery performed by a team of specialized surgeons. Over the past year, the center has seen a



continuous increase in patient trust, particularly among those suffering from osteoarthritis, herniated discs, back and neck pain, as well as injuries from accidents and sports. This includes procedures such as total knee replacement and spinal disc surgery.

**The Diabetes Center** is a comprehensive care facility dedicated to improving patients' quality of life through continuous care, from the early stages of the disease to the prevention of long-term complications. Over the past year, the center has enhanced its proactive screening efforts by conducting blood tests for Pre-Diabetes Mellitus. The screening has also been extended to high-risk groups, particularly family members of existing patients, to ensure early detection and provide prompt, appropriate medical care. Furthermore, the center emphasizes empowering patients and their families through educational activities on diabetes management, complication prevention, dietary control, lifestyle modification, and proper exercise. These initiatives have been conducted both within the hospital and through external outreach programs, such as World Diabetes Day activities and mobile screening units at senior citizen clubs.

**The Emergency Department** provides 24-hour medical care for urgent conditions and accidents, staffed by a team of emergency medicine physicians, nurses, and specialized personnel. Equipped with standardized medical equipment, the department ensures that patients receive rapid, safe, and highly effective treatment.

Over the past year, the Emergency Department played a vital role in supporting the province's emergency medical services by providing medical standby and safety coverage for Chonburi provincial sports competitions and the SEA Games. This reflects our potential and readiness to handle emergencies at large-scale events.

Furthermore, the hospital enhances patient convenience by facilitating claims under the Protection for Motor Vehicle Victims Act, B.E. 2535. Patients can immediately access the initial medical coverage of up to 30,000 Baht, effectively reducing their out-of-pocket expenses following an accident.

The Emergency Department also maintains close cooperation with rescue foundations and local emergency medical networks to improve the efficiency of timely patient transfers. These efforts have resulted in continuous public trust and have strengthened the hospital's role in provincial emergency medicine.

**The Pediatrics and Obstetrics-Gynecology Departments** provide comprehensive healthcare for women, mothers, children, and families, with a strong focus on preventive health across all life stages.

Regarding the Pediatrics Department, the hospital has expanded its vaccination services, offering both mandatory basic vaccines and optional vaccines to meet the needs of parents who prioritize disease prevention and immunization for their children. Additionally, the department



organized Children's Day activities and consistently conducted health awareness programs at local schools to promote children's well-being and foster strong community relations.

**Mr.Kesada Chandsawang, M.D.** Presenting the performance of Aikchol Angsila Hospital

The meeting was informed of the name change of Aikchol 2 Hospital to Aikchol Angsila Hospital, effective October 14, 2025. The objective of this rebranding is to enhance brand recall by incorporating the hospital's location into its name. Aikchol Angsila Hospital serves various customer segments, including premium, self-pay, life insurance, and Social Security beneficiaries. The operating results of Aikchol Angsila Hospital were then presented as follows:

**The Pediatrics Department** is fully operational 24 hours a day, ensuring that children who fall ill at night do not have to wait until morning for medical attention. We understand that every minute a child is sick is a time of great concern for parents. Aikchol Ang Sila Hospital is ready to provide immediate care for your little ones without delay. With our team of experienced pediatricians, we are dedicated to ensuring the physical comfort of children and peace of mind for parents throughout the night.

**The ICU and Inpatient Departments (IPD)** are fully prepared for all medical crises with a team of highly skilled physicians. We elevate peace of mind beyond medical treatment by providing a 'serene and safe space' for both physical and mental recovery. Furthermore, the hospital has renovated its inpatient rooms and ICU Isolation rooms with negative pressure systems. These facilities prioritize safety through international standard air circulation systems that control and prevent the spread of pathogens. The rooms offer a private and quiet atmosphere with minimal noise disturbance to foster optimal recovery. We believe that effective treatment begins with attention to every detail.

**Trauma Center** due to the strategic location of Aikchol Ang Sila Hospital near tourist attractions and industrial estates, we consistently receive patients with injuries from traffic and industrial accidents. We have implemented an efficient patient transfer system and utilize advanced diagnostic technologies, such as CT Scan and MRI, to ensure rapid and safe treatment. Furthermore, we have recruited specialists in relevant fields to support emergency medical services, including emergency medicine physicians, trauma surgeons, vascular surgeons, and critical care physicians.

In 2025, the hospital received approximately 1,211 cases transferred by the Tri Kunna Tham Foundation (Sam Tek Thai) Chonburi and the Dhamma Ratsami Maneerat Foundation. This represents an increase of approximately 34% compared to 2024.

**Regarding the General Surgery and Orthopedic Departments**, in 2025, Aikchol Ang Sila Hospital introduced Laparoscopic Surgery (minimally invasive surgery) to patients under all types of healthcare coverage. This laparoscopic technology offers significant benefits, including faster recovery times and reduced complications, allowing patients to return to their normal lives more quickly.



**Ms.Daraphan Sakornsatian**, reported that 2025 marked the inaugural year of the 'Health Fair' event, organized to revitalize the reputation and brand image of both Aikchol Hospital and Aikchol Ang Sila Hospital. The 1st Aikchol Health Fair was held at the activity area of Central Plaza Chonburi.

**Mr.Sittipot Manoch**, reported on the Company's overall accounting and financial performance. In 2025, the combined total revenue of both hospitals reached Baht 1,794.99 million, an increase of Baht 48.20 million or 2.8% from 2024. This growth was primarily driven by an increase in Outpatient Department (OPD) revenue from Non-Communicable Diseases (NCDs), such as hypertension, diabetes, and cardiovascular diseases. Additionally, the 'Aikchol Health Fair' held at Central Chonburi in November resulted in a higher volume of health check-up services.

Revenue from the Social Security Scheme increased due to higher claims for high-cost care (AdjRW  $\geq$  2) and risk-based payments (chronic diseases). Furthermore, while revenue had previously declined in late 2024 following the Social Security Office's announcement to reduce reimbursement rates for high-cost care (AdjRW  $\geq$  2), rates returned to normal levels in 2025.

Other income decreased by Baht 7.97 million compared to the previous year, primarily due to lower interest income resulting from the decreased value of debt instruments.

Total combined costs and administrative expenses for both hospitals amounted to Baht 1,653.98 million, a slight increase of Baht 7.39 million or 0.4% from the prior year. Medical treatment costs in 2025 were Baht 1,427.34 million, a decrease of Baht 5.51 million or -0.4%, mainly due to cost-control measures for drugs and medical supplies. However, medical personnel costs and staff salaries increased in line with treatment revenue. Additionally, there was higher depreciation from investments in building renovations and medical equipment to support more complex treatments.

The Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) amounted to Baht 280.41 million, an increase of Baht 38.45 million or 15.9% compared to 2024. The Company's EBITDA Margin improved to 15.2%, compared to 13.4% in 2024.

For the year 2025, the Company reported a net profit of Baht 153.74 million, an increase of Baht 26.73 million or 21.0% from the previous year. Basic earnings per share (EPS) for 2025 and 2024 were Baht 1.03 and Baht 0.85, respectively. Total comprehensive income for 2025 was Baht 126.54 million, an increase of Baht 16.06 million or 14.5% year-on-year. This resulted from the net profit growth of Baht 26.73 million, offset by items that will not be reclassified subsequently to profit or loss. These items included a Baht 13.33 million decrease in the fair value (net of tax) of equity instruments in Bangkok Dusit Medical Services PCL (BDMS) and a Baht 2.67 million increase in income tax related to items that will not be reclassified.

Significant changes in assets as of December 31, 2025, are as follows:



Cash and cash equivalents: Stood at Baht 229.81 million, a decrease of Baht 18.94 million from the previous year. This was primarily due to the Company allocating cash flow from operations to further invest in government debt instrument mutual funds.

Trade and other current receivables: Amounted to Baht 104.05 million, an increase of Baht 11.02 million year-on-year. The majority consists of current trade receivables that are not yet due and are within the Company's standard credit terms. The average collection period is 20 days. These are high-quality receivables from government agencies, insurance companies, life insurance companies, and corporate contract partners.

The Company reviews the allowance for doubtful accounts and bad debt write-offs on a quarterly basis, in accordance with the established accounting standards.

Other current financial assets: Amounted to Baht 1,158.20 million, an increase of Baht 130.88 million from the previous year. This was due to the Company allocating cash flow from operations to increase its investment in government debt instrument mutual funds.

Property, plant, and equipment, net: Stood at Baht 724.85 million, a decrease of Baht 31.31 million year-on-year. While the Company invested in medical equipment to expand its capacity for complex medical care and renovated inpatient wards, there was an increase in accumulated depreciation recognized for the period. This represents a systematic allocation of asset costs over their useful lives to reflect true value in accordance with financial reporting standards.

The Chairman clarified the factors and events that may significantly impact the Company's financial position and operations. The overall private hospital industry continues to show an upward growth trend, driven by the increasing demand for high-quality medical treatment and the transition towards the era of Precision Medicine, alongside structural shifts into an aging society.

Despite the limited growth rate of the domestic economy, the recovery of international patient groups in certain regions through Medical Tourism and the transition toward becoming a 'Smart Hospital' remain key drivers and opportunities for growth—a goal the Company is actively striving toward.

Regarding the competitive landscape of the private hospital sector, Aikchol Hospital is strategically located within the Eastern Economic Corridor (EEC), which has led to intensified market competition. To address this, the Company is committed to exploring new innovations and business evolutions to differentiate our services and mitigate aggressive competition. We will keep our shareholders informed of any further developments in due course.

On ESG (Environmental, Social, and Governance) matters, in 2025, the Company began implementing related activities in earnest by establishing working groups at both the board and hospital levels. We have initiated a partnership with the Chonburi Provincial Environmental Office, with more concrete collaborations expected this year.



In the Social aspect, throughout 2025, the Company conducted community outreach programs in surrounding areas and industrial estates. These programs provided health education, hygiene awareness, and Basic Life Support (BLS) training to various agencies to ensure that Aikchol Hospital and Aikchol Angsila Hospital remain truly trusted by the community.

Regarding Governance, the Company continues to prioritize medical ethics in providing inclusive care for all patients. This includes strictly adhering to the Personal Data Protection Act (PDPA) to ensure the protection of our service users' data.

The Chairman then provided an opportunity for shareholders to ask questions or express opinions regarding this agenda item. No shareholders raised any questions or expressed any further opinions.

**Meeting Resolution** The meeting acknowledged the Company's performance report and the Company's Board of Directors' report for 2025.

**Agenda 2 Consideration and approval of the financial statements for the year 2025, ending on 31 December 2025.**

The Chairman assigned Mrs.Thitawat Pothanant, Member of the Audit Committee, to report on this agenda item.

Mrs.Thitawat Pothanant presented a summary of the Statement of Financial Position and the Statement of Comprehensive Income for the year ended December 31, 2025. These financial statements were audited and signed by Ms.Potjanarat Siripipat, Certified Public Accountant No. 9012, from Dharmniti Auditing Co., Ltd. The auditor expressed an opinion that the Company's separate financial statements present fairly, in all material respects, in accordance with Financial Reporting Standards.

The Chairman proposed that the Annual General Meeting of Shareholders consider and approve the Company's financial statements for the year ended December 31, 2025.

The Chairman then provided an opportunity for shareholders to ask questions or express opinions. No shareholders raised any questions or comments.

Subsequently, the Company Secretary, as assigned by the Chairman, requested the meeting to cast their votes to approve the financial statements for the year ended December 31, 2025. This agenda item requires a majority vote of the shareholders attending the meeting and casting their votes.



**Meeting Resolution** The meeting considered and resolved to approve the financial statements for the year 2025 ending on December 31, 2025 with the following votes:

Vote	Number of Votes	% of Total Votes*
Approve	86,634,349	100.0000
Disapprove	0	0.0000
Abstain	0	0.0000
Void	0	0.0000
<b>Total</b>	<b>86,634,349</b>	<b>100.0000</b>

\*Percentage of total votes of shareholders and proxies who attended the meeting and had the right to vote

For this agenda item, 4 additional shareholders joined the meeting, representing 231,984 shares. This brought the total number of attendees to 38, representing a total of 86,634,349 shares, or 57.7912% of the Company's total issued shares.

### **Agenda 3 Consideration and approval of the allocation of profits from operating results and payment of annual dividends for 2025**

Regarding the legal reserve allocation, Section 116 of the Public Limited Companies Act B.E. 2535 (including its amendments) and Article 46 of the Company's Articles of Association stipulate that: 'The Company must allocate at least 5% of its annual net profit, less any accumulated losses brought forward (if any), to a reserve fund until this fund reaches no less than 10% of the registered capital.' As the Company's legal reserve has already reached 10% of its registered capital, no further allocation to the legal reserve is required. According to the Company's dividend policy, unless there is a necessary reason, the Board of Directors intends to propose a dividend payment of no less than 50% of the net profit after tax.

The Chairman informed the meeting that for the 2025 operating results (from January 1, 2025, to December 31, 2025), the Company recorded a net profit after tax of Baht 153,737,905.

The Chairman, therefore, proposed the approval of the profit appropriation and the 2025 annual dividend payment at the rate of Baht 0.52 per share, totaling Baht 77,952,817.28. This represents 50.71% of the net profit after tax. All dividends will be subject to withholding tax at the rate prescribed by law. The record date for shareholders entitled to receive the dividend is set for May 5, 2025, and the dividend payment date is scheduled for May 20, 2025.

The Chairman then provided an opportunity for shareholders to ask questions or express opinions. No shareholders raised any questions or comments.



Subsequently, the Company Secretary, as assigned by the Chairman, requested the meeting to cast their votes to approve the 2025 dividend payment and profit appropriation. This agenda item requires a majority vote of the shareholders attending the meeting and casting their votes.

**Meeting Resolution** The meeting considered and resolved to approve the allocation of profits from operating results and the payment of annual dividends for 2025 with the following votes:

Vote	Number of Votes	% of Total Votes*
Approve	86,634,349	100.0000
Disapprove	0	0.0000
Abstain	0	0.0000
Void	0	0.0000
<b>Total</b>	<b>86,634,349</b>	<b>100.0000</b>

\*Percentage of total votes of shareholders and proxies who attended the meeting and had the right to vote

**Agenda 4 Consideration of approval of appointment of directors to replace directors whose terms have expired.**

The Chairman assigned the Company Secretary to carry out this agenda.

The Company Secretary informed the meeting that, pursuant to Section 71 of the Public Limited Companies Act B.E. 2535 (including its amendments) and Article 22 of the Company's Articles of Association, one-third of the directors must retire by rotation at every Annual General Meeting. If the number of directors is not a multiple of three, the number nearest to one-third shall retire. Currently, there are 7 directors on the Board. In 2025, the following 3 directors are due to retire by rotation:

1. Assistant Professor Dr.Kritsada Banchuen, Independent Director, Chairman of the Audit Committee, and Chairman of the Nomination and Remuneration Committee, has expressed his intention not to seek re-election for another term.
2. Mrs. Thitawat Pothanant: Independent Director and Member of the Audit Committee.
3. Ms. Oranuch Wanich: Director.

The Board of Directors, having carefully and prudently considered the candidates' qualifications, educational backgrounds, experience, and expertise relevant to the business, proposes that the Annual General Meeting of Shareholders re-appoint the two retiring directors to serve for another term.



Subsequently, the Company Secretary, as assigned by the Chairman, requested the meeting to cast their votes to re-elect the 2 directors. For this agenda item, shareholders or proxies are required to vote for each director individually. The resolution must be passed by a majority vote of the shareholders attending the meeting and casting their votes.

**Meeting Resolution** The meeting considered the matter and resolved to approve the re-election of the 2 directors to their positions for another term, with the following voting results of the shareholders attending the meeting and casting their votes:

**1. Mrs.Thitawat Pothanant**

Vote	Number of Votes	% of Total Votes*
Approve	86,634,349	100.0000
Disapprove	0	0.0000
Abstain	0	0.0000
Void	0	0.0000
<b>Total</b>	<b>86,634,349</b>	<b>100.0000</b>

\*Percentage of total votes of shareholders and proxies who attended the meeting and had the right to vote

**2. Ms.Oranuch Wanich**

Vote	Number of Votes	% of Total Votes*
Approve	86,634,349	100.0000
Disapprove	0	0.0000
Abstain	0	0.0000
Void	0	0.0000
<b>Total</b>	<b>86,634,349</b>	<b>100.0000</b>

\*Percentage of total votes of shareholders and proxies who attended the meeting and had the right to vote

**Agenda 5 Consideration and approval of the appointment of new directors and authorized signatories.**

The Company provided an opportunity for shareholders to nominate qualified candidates in accordance with the Public Limited Companies Act B.E. 2535 (1992), the Securities and Exchange Act B.E. 2535 (1992), and the regulations of the Stock Exchange of Thailand (SET), the Securities and Exchange Commission (SEC), the Capital Market Supervisory Board, as well as the Company's Corporate



Governance principles. The nomination period was open from October 1, 2025, to December 31, 2025, via the Company's website.

It appeared that one shareholder nominated a candidate for the directorship: Mr.Bordin Sabsomboon. The Company has verified his qualifications against the criteria set by the SET, the SEC, and other regulatory bodies. After careful and diligent consideration, the Company deems it appropriate to propose the appointment of Mr.Bordin Sabsomboon as a director of the Company.

**Meeting Resolution** The Meeting, after due consideration, resolved with a unanimous vote to approve the appointment of Mr.Bordin Sabsomboon as a new director. The voting results of the shareholders who attended the meeting and were entitled to vote are as follows:

**Mr.Bordin Sabsomboon**

Vote	Number of Votes	% of Total Votes*
Approve	86,634,349	100.0000
Disapprove	0	0.0000
Abstain	0	0.0000
Void	0	0.0000
<b>Total</b>	<b>86,634,349</b>	<b>100.0000</b>

\*Percentage of total votes of shareholders and proxies who attended the meeting and had the right to vote

**Agenda 6 Consideration and approval of director remuneration**

The Chairman stated to the meeting that based on the opinions of the Nomination and Remuneration Committee and the Board of Directors, it was deemed appropriate to propose to the general meeting of shareholders to consider approving the remuneration of the directors in 2026 to be the same as in 2025, with no changes, as follows:

1. The remuneration of the directors	2026 (Proposed Year)	2025
1.1 Meeting allowance		
1.1.1 Chairman	15,000 Baht / Meeting	15,000 Baht / Meeting
1.1.2 Each Director	12,000 Baht / Meeting	12,000 Baht / Meeting
1.2 Monthly Compensation		
1.2.1 Chairman	30,000 Baht / Meeting	30,000 Baht / Meeting
1. The remuneration of the directors	2025 (Proposed Year)	2024
1.2.2 Each Director	20,000 Baht / Meeting	20,000 Baht / Meeting
1.3 Remuneration*	Totaling 7.2 Million Baht	Totaling 7.2 Million Baht



1.4	Other benefits	Medical expenses not more than 500,000 Baht / person	Medical expenses not more than 500,000 Baht / person
<b>2. Sub-Committee</b>		<b>2025 (Proposed Year)</b>	<b>2024</b>
<b>2.1</b>	<b>The Audit Committee</b>		
2.1.1	Meeting allowance		
2.1.1.1	Chairman	12,000 Baht / Meeting	12,000 Baht / Meeting
2.1.1.2	Each Director	10,000 Baht / Meeting	10,000 Baht / Meeting
2.1.2	Monthly Compensation		
2.1.2.1	Chairman	-None-	-None-
2.1.2.2	Each Director	-None-	-None-
2.1.3	Other benefit	-None-	-None-
<b>2.2</b>	<b>The Nomination and Remuneration Committee</b>		
2.2.1	Meeting allowance		
2.2.1.1	Chairman	12,000 Baht / Meeting	12,000 Baht / Meeting
2.2.1.2	Each Director	10,000 Baht / Meeting	10,000 Baht / Meeting
2.2.2	Monthly Compensation		
2.2.2.1	Chairman	-None-	-None-
2.2.2.2	Each Director	-None-	-None-
2.2.3	Other benefit	-None-	-None-
<b>2.3</b>	<b>The Executive Committee</b>		-None-
2.3.1	Meeting allowance	-None-	-None-
2.3.1.1	Chairman	-None-	-None-
2.3.1.2	Each Director	-None-	-None-
2.3.2	Remuneration	-None-	-None-
2.3.3	Other benefit	-None-	-None-

\* The gratuity for directors shall be allocated among the directors as deemed appropriate by the Board of Directors.

The shareholders were given the opportunity to ask questions or express their opinions on this agenda item, but it turned out that no shareholders asked questions or expressed their opinions.

The Company Secretary, who was assigned by the Chairman, then proposed to the meeting to consider and vote to approve the remuneration of the said directors, which this agenda must be



approved by no less than 2/3 of the total number of votes of shareholders attending the meeting and having the right to vote.

**Meeting Resolution** The meeting considered and resolved to approve the remuneration of the directors with the following votes:

Vote	Number of Votes	% of Total Votes*
Approve	86,634,349	100.0000
Disapprove	0	0.0000
Abstain	0	0.0000
Void	0	0.0000
<b>Total</b>	<b>86,634,349</b>	<b>100.0000</b>

\*Percentage of total votes of shareholders and proxies who attended the meeting and had the right to vote

**Agenda 7 To consider and approve the appointment of auditors and determine the audit fee for the year 2026**

The Chairman assigned the Company Secretary to proceed with this agenda item. The Company Secretary informed the meeting that the Board of Directors, based on the recommendation of the Audit Committee, proposed that the Annual General Meeting of Shareholders appoint the auditors and determine the audit fee for Dharmniti Auditing Co., Ltd. The details are as follows:

1. Ms. Potjanarat Siripipat License number 9012 or
2. Mr. Thanawut Piboonsawat License number 6699 or
3. Ms. Techinee Pornpenpob License number 10769 or
4. Other auditors approved by the Securities and Exchange Commission, which Dharmniti Auditing Company Limited has assigned to be responsible auditors

In this regard, none of the proposed auditors has any relationship with or interest in the Company, its executives, major shareholders, or any persons related thereto. Each auditor has served as the Company's auditor for a total of 7 years. The Board also proposes the audit fee for the year 2026 in the amount of Baht 1,000,000 (One Million Baht Only). Details are as follows:

1. Review quarterly financial statements  
170,000 baht per quarter x 3 quarters 510,000.- Baht



2. Review of the 2026 annual financial statements, including the control assessment

General interior of computer systems for accounting processing

General Control and check the inventory twice a year 490,000.- Baht

Total 1,000,000.- Baht

The shareholders were given the opportunity to ask questions or express their opinions on this agenda item, but it turned out that no shareholders asked questions or expressed their opinions.

The Company Secretary, who was assigned by the Chairman, then proposed to the meeting to consider and approve the appointment of the auditor and the auditor's remuneration, which this agenda must be approved by a majority vote of the shareholders who attended the meeting and had the right to vote.

**Meeting Resolution** The meeting considered and resolved to approve the appointment of auditors and determine the auditors' remuneration for the year 2026.

Vote	Number of Votes	% of Total Votes*
Approve	86,634,349	100.0000
Disapprove	0	0.0000
Abstain	0	0.0000
Void	0	0.0000
<b>Total</b>	<b>86,634,349</b>	<b>100.0000</b>

\*Percentage of total votes of shareholders and proxies who attended the meeting and had the right to vote

#### **Agenda 8 Other matters (if any)**

-None-

The Chairman stated to the meeting that the Company had opened opportunities for shareholders to propose agenda items by announcing the criteria and procedures for proposing agenda items from 1 October 2025 to 31 December 2025 via the Company's website. As a result, no shareholders proposed any agenda items to the Company. Therefore, there were no other matters for consideration in this agenda item.



At the end of the Annual General Meeting, shareholders raised additional questions, and the Company Secretary read out the suggestions submitted by shareholders via electronic mail. The details of the questions, answers, and suggestions have been documented and attached as an appendix to the minutes of the meeting.

The Chairman thanked all shareholders for attending the meeting and for their continued support of the Company, and closed the meeting.

The meeting closed at 11:00 AM.

Sign.....Mr. Apirag Vanich.....The Chairperson of the Meeting  
(Mr. Apirag Vanich)

Sign.....Mrs. Wilailux Srisuwan.....Company Secretary  
(Mrs. Wilailux Srisuwan)  
Meeting Minutes



**Attachments**  
**Questions - Answers**  
**Annual General Meeting of Shareholders 2026 (48<sup>th</sup>)**  
**Aikchol Hospital Public Company Limited**

---

**Proxy: Mr. Akawat Prachasak**, Shareholders' Rights Protection Volunteer, representing the Thai Investors Association.

**Question 1:** Regarding the new HIS (Hospital Information System) and ERP (Enterprise Resource Planning) systems implemented last year, in which quarter of 2026 do you expect to see a measurable impact on reducing personnel expenses or improving gross profit margins? Additionally, are there any specific data security risks concerning patient information that remain a primary concern?

**Question 2:** Amidst intensifying competition in the Chonburi and EEC (Eastern Economic Corridor) areas, what are the company's proactive strategies for retaining the existing customer base and expanding into new general and international patient segments? Furthermore, how will the implementation of the new hospital information system enhance the patient experience to increase visit frequency or the average revenue per patient?

**Respondent: Mr. Bordin Sapsomboon, Director**

**Answer 1:** The implementation of these IT systems is highly efficient and beneficial. However, because our two hospitals currently use different systems and are large-scale operations with a significant number of personnel, some initial obstacles may arise during the transition. Regarding data security risks, we place the highest priority on this matter. We believe that maintaining a secure system does not rely on technology alone; the most crucial factor is ensuring that our personnel are fully aware of and understand the importance of data security.

**Respondent: Mr. Siripoj Manoch, Assistant Chairman of the Executive Board (Corporate Strategy)**

**Answer 2:** Strategically located as Chonburi's first private hospital, we prioritize retaining our base through CRM, tailored packages, and family-oriented care for both individuals and corporate partners. Our international patients (Japanese, Chinese, Taiwanese) are primarily local expatriates rather than tourists, and our services are fully equipped to support all segments.

The meeting acknowledged the aforementioned suggestions.

.....